Abstract 4099
Background
The aim of this study was to analyze the safety and effectiveness of different preoperative preparation time in the neoadjuvant chemotherapy (SOX) regimen in patients with advanced gastric cancer.
Methods
From June 1 2010 to June 1 2017, 120 patients aged from 25 to 80 with clinical stage IIA-IIIC gastric cancer received neoadjuvant chemotherapy with S-1 and oxaliplatin and radical gastrectomy in Chinese PLA General Hospital. They were eligible for inclusion and they were randomly assigned to either the 3-weeks group, which received radical gastrectomy 3 weeks after neoadjuvant chemotherapy (n = 60), or the 5-weeks group, which received radical gastrectomy 5 weeks after neoadjuvant chemotherapy (n = 60). We compared short-term surgical outcomes between the two groups.
Results
There were no significant differences between the two groups regarding the clinical pathological characteristics. However, the 5-weeks group had less intraoperative blood loss (229 ml vs 240 ml, P = 0.031) and less Clavien-Dindo grade II to IV complications (P = 0.006) than the 3-weeks group. Baseline clinicopathologic characteristics, and short-term outcomes of the patients treated in the two groups were similar.
Conclusions
Patients with advanced gastric cancer undergoing advanced neoadjuvant chemotherapy after neoadjuvant chemotherapy require a certain amount of time to adjust and prepare for gastrectomy. Considering the general condition of the patients, the preoperative interval can be shortened and the efficacy can be improved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract